GeneTex
United States (US)

DcR2 / CD264 peptide

Cat No. GTX28379

Application Blocking
Species Human
APPLICATION

Application Note

The peptide is used for blocking the activity of GTX22019. Incubatingthe peptide with equal volume of antibody for 30 min at 37ºC usually completely blocks theantibody activity in Western blotting.
PROPERTIES

Form

Liquid

Buffer

PBS pH7.2 with 10 mM NaH2PO4, 10 mM Na2HPO4, 130 mM NaCl, 0.1% bovine serum albumin, and 0.02% sodium azide

Concentration

0.20mg/ml(Please refer to the vial label for the specific concentration.)

Conjugation

Unconjugated

Note

For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
TARGET

Synonyms

Tnf Receptor Superfamily Member 10D,Cd264,Dcr2,Trail-R4,Trailr4,Trundd,Tnfrsf10D

Background

Apoptosis is induced by certain cytokines including TNF and Fas ligand in the TNF family through their death domain containing receptors. TRAIL/Apo2L, a member of the TNF family, induces apoptosis of a variety of tumor cell lines. DR4 and DR5 are functional receptors for TRAIL, and DcR1/TRID is a decoy receptor. Another member of the TRAIL receptor family was identified and designated DcR2 (Marsters et al., 1997; Degli-Esposti et al., 1997; Pan et al., 1998). The DcR2 receptor is 386 amino acids in length and has an extracellular TRAIL binding domain, but lacks intracellular death domain and does not induce apoptosis. Although this receptor binds to the cytotoxic ligand TRAIL, it contains a truncated death domain and functions as an inhibitory receptor. When overexpressed, the DcR2 receptor can protect cells against TRAIL mediated cytotoxicity. Like DR4 and DR5, DcR2 transcript is widely expressed in a variety of normal human tissues but DcR2 is absent in most tumors. Ultraviolet radiation has been shown to upregulate DcR2 expression on human keratinocytes. Over expression of DcR2 attenuated TRAIL induced apoptosis.

Research Area

Package List Price ($)
$ 179